The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Introduction to Fragment-Based Drug Discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy
Mayer, M., & Meyer, B. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990614)38:12<1784::aid-anie1784>3.0.co;2-q · Cited by 1,595
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
On the attribution and additivity of binding energies
Jencks, W. P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4046 · Cited by 912
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
Self-citationThe influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs
Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030191r · Cited by 476
Site-directed ligand discovery
Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466
Self-citationFink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., et al. (2008) · Science · doi:10.1126/science.1159961 · Cited by 452
Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
A detergent-based assay for the detection of promiscuous inhibitors
Feng, B. Y., & Shoichet, B. K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.77 · Cited by 429
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T. L., Homans, S. W., Kessler, H., Luchinat, C., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2606 · Cited by 414
Adding calorimetric data to decision making in lead discovery: a hot tip
Ladbury, J. E., Klebe, G., & Freire, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3054 · Cited by 398
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Self-citationNonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Concepcion, J., Witte, K., Wartchow, C., Choo, S., Yao, D., Persson, H., Wei, J., Li, P., Heidecker, B., Ma, W., et al. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709789104915 · Cited by 357
Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
Discovering novel ligands for macromolecules using X-ray crystallographic screening
Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., & Greer, J. (2000) · Nature Biotechnology · doi:10.1038/80319 · Cited by 322
Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
Hajduk, P. J., Sheppard, G., Nettesheim, D. G., Olejniczak, E. T., Shuker, S. B., Meadows, R. P., Steinman, D. H., Carrera, G. M., Marcotte, P. A., Severin, J., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9702778 · Cited by 317
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis
Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 292
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100060b · Cited by 264
Structural biology in fragment-based drug design
Murray, C. W., & Blundell, T. L. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.04.003 · Cited by 208
Caflisch, A., Miranker, A., & Karplus, M. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00067a013 · Cited by 208
From fragment to clinical candidate—a historical perspective
Chessari, G., & Woodhead, A. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.007 · Cited by 202
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
SPR-based Fragment Screening: Advantages and Applications
Neumann, T., Junker, H.-D., Schmidt, K., & Sekul, R. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341073 · Cited by 189
Docking, virtual high throughput screening and in silico fragment‐based drug design
Zoete, V., Grosdidier, A., & Michielin, O. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00665.x · Cited by 184
Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100059d · Cited by 184
Fragment‐based Approaches in Drug Discovery
(2006) · Methods and Principles in Medicinal Chemistry · doi:10.1002/3527608761 · Cited by 181
Observations on Screening-Based Research and Some Concerning Trends in the Literature
Baell, J. B. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.237 · Cited by 179
Babaoglu, K., Simeonov, A., Irwin, J. J., Nelson, M. E., Feng, B., Thomas, C. J., Cancian, L., Costi, M. P., Maltby, D. A., Jadhav, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701500e · Cited by 178
Transforming fragments into candidates: small becomes big in medicinal chemistry
de Kloe, G. E., Bailey, D., Leurs, R., & de Esch, I. J. P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.009 · Cited by 178
Brough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900357y · Cited by 173
NMR methods in fragment screening: theory and a comparison with other biophysical techniques
Dalvit, C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.013 · Cited by 167
Grading the commercial optical biosensor literature—Class of 2008: ‘The Mighty Binders’
Rich, R. L., & Myszka, D. G. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.1004 · Cited by 167
Fragment Screening by Surface Plasmon Resonance
Navratilova, I., & Hopkins, A. L. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900002k · Cited by 166
Fragment-based screening using X-ray crystallography and NMR spectroscopy
Jhoti, H., Cleasby, A., Verdonk, M., & Williams, G. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.07.010 · Cited by 166
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Limitations and lessons in the use of X-ray structural information in drug design
Davis, A. M., St-Gallay, S. A., & Kleywegt, G. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.006 · Cited by 161
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D. V., Krupka, H. I., England, B. P., Arnold, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811325106 · Cited by 151
Fragment-based lead discovery: a chemical update
Erlanson, D. A. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.007 · Cited by 149
Self-citationWendt, M. D., Wang, S., Kunzer, A. R., McClellan, W. J., Bruncko, M., Oost, T. K., Ding, H., Joseph, M. K., Zhang, H., Nimmer, P. M., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050754u · Cited by 138
Recent progress in fragment-based lead discovery
Schulz, M. N., & Hubbard, R. E. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.04.009 · Cited by 136
Albert, J. S., Blomberg, N., Breeze, A. L., Brown, A., Burrows, J. N., Edwards, P. D., Folmer, R. H. A., Geschwindner, S., Griffen, E., Kenny, P. W., et al. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341091 · Cited by 126
Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography
Davies, D. R., Mamat, B., Magnússon, Ó. Þ., Christensen, J., Haraldsson, M. H., Mishra, R. K., Pease, B., Hansen, E., Singh, J., Zembower, D. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900259h · Cited by 122
Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies
Huth, J. R., Park, C., Petros, A. M., Kunzer, A. R., Wendt, M. D., Wang, X., Lynch, C. L., Mack, J. C., Swift, K. M., Judge, R. A., et al. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00535.x · Cited by 119
Impact of linker strain and flexibility in the design of a fragment-based inhibitor
Chung, S., Parker, J. B., Bianchet, M. A., Amzel, L. M., & Stivers, J. T. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.163 · Cited by 118
Akritopoulou‐Zanze, I., & Hajduk, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.002 · Cited by 116
A Novel Class of Small Molecule Inhibitors of Hsp90
Yi, F., & Regan, L. (2008) · ACS Chemical Biology · doi:10.1021/cb800162x · Cited by 116
Johnston, P. A., Soares, K. M., Shinde, S. N., Foster, C. A., Shun, T. Y., Takyi, H. K., Wipf, P., & Lazo, J. S. (2008) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.151 · Cited by 113
Fragment-based approaches to enzyme inhibition
Ciulli, A., & Abell, C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.003 · Cited by 109
Fragment-Based Screening Using Surface Plasmon Resonance Technology
Perspicace, S., Banner, D. W., Benz, J., Müller, F., Schlatter, D., & Huber, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109332595 · Cited by 109
Mpamhanga, C. P., Spinks, D., Tulloch, L. B., Shanks, E. J., Robinson, D. A., Collie, I. T., Fairlamb, A. H., Wyatt, P. G., Frearson, J. A., Hunter, W. N., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900414x · Cited by 105
Docking for fragment inhibitors of AmpC β-lactamase
Teotico, D. G., Babaoglu, K., Rocklin, G. J., Ferreira, R. S., Giannetti, A. M., & Shoichet, B. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813029106 · Cited by 102
Soares, K. M., Blackmon, N. L., Shun, T. Y., Shinde, S. N., Takyi, H. K., Wipf, P., Lazo, J. S., & Johnston, P. A. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0247 · Cited by 101
Becattini, B., Culmsee, C., Leone, M., Zhai, D., Zhang, X., Crowell, K. J., Rega, M. F., Landshamer, S., Reed, J. C., Plesnila, N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603460103 · Cited by 94
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ
Czaplewski, L. G., Collins, I., Boyd, E. A., Brown, D., East, S. P., Gardiner, M., Fletcher, R., Haydon, D. J., Henstock, V., Ingram, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.021 · Cited by 91
Divergent modes of enzyme inhibition in a homologous structure-activity series.
Ferreira, R. S., Bryant, C., Ang, K. K. H., McKerrow, J. H., Shoichet, B. K., & Renslo, A. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009229 · Cited by 88
Native Ms: An ‘Esi’ Way to Support Structure- and Fragment-Based Drug Discovery
Vivat, V., Atmanène, C., Zeyer, D., DORSSELAER, A. V., & Cianférani, S. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.141 · Cited by 87
Drugging challenging targets using fragment-based approaches
Coyne, A. G., Scott, D. E., & Abell, C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.010 · Cited by 86
The SeeDs Approach: Integrating Fragments into Drug Discovery
Hubbard, R. E., Davis, B. J., Chen, I., & Drysdale, M. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782341109 · Cited by 86
Fragment Screening Using X-Ray Crystallography
Davies, T. G., & Tickle, I. J. (2011) · Topics in current chemistry · doi:10.1007/128_2011_179 · Cited by 82
Sledz, P., Silvestre, H. L., Hung, A. W., Ciulli, A., Blundell, T. L., & Abell, C. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100595u · Cited by 78
NMR-based techniques in the hit identification and optimisation processes
Pellecchia, M., Becattini, B., Crowell, K. J., Fattorusso, R., Forino, M., Fragai, M., Jung, D., Mustelin, T., & Tautz, L. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.597 · Cited by 77
Früh, V., Zhou, Y., Chen, D., Loch, C., Eiso, A. B., Grinkova, Y. N., Verheij, H. J., Sligar, S. G., Bushweller, J. H., & Siegal, G. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.06.011 · Cited by 76
Penning, T. D., Chandrakumar, N. S., Chen, B. B., Chen, H. Y., Desai, B. N., Djurić, S. W., Docter, S. H., Gasiecki, A. F., Haack, R. A., Miyashiro, J. M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990496z · Cited by 71
A Simple Assay for Detection of Small-Molecule Redox Activity
Lor, L. A., Schneck, J. L., McNulty, D. E., Diaz, E., Brandt, M. A., Thrall, S. H., & Schwartz, B. K. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107304113 · Cited by 71
Thermodynamic Optimisation in Drug Discovery: A Case Study using Carbonic Anhydrase Inhibitors
Scott, A. D., Phillips, C., Alex, A., Flocco, M. M., Bent, A., Randall, A., O’Brien, R., Damian, L., & Jones, L. H. (2009) · ChemMedChem · doi:10.1002/cmdc.200900386 · Cited by 69
Sandanayaka, V. P., Mamat, B., Mishra, R. K., Winger, J., Krohn, M., Zhou, L.-M., Keyvan, M., Enache, L. A., Sullins, D. W., Onua, E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900838g · Cited by 64
(2009) · Wiley eBooks · doi:10.1002/9780470524961 · Cited by 60
Wyss, D. F., Wang, Y., Eaton, H. L., Strickland, C., Voigt, J. H., Zhu, Z., & Stamford, A. W. (2011) · Topics in current chemistry · doi:10.1007/128_2011_183 · Cited by 59
NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability
Hajduk, P. J., Shuker, S. B., Nettesheim, D. G., Craig, R., Augeri, D. J., Betebenner, D. A., Albert, D. H., Guo, Y. P., Meadows, R. P., Xu, L., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020160g · Cited by 57
The multiple roles of computational chemistry in fragment-based drug design
Law, R., Barker, O., Barker, J. J., Hesterkamp, T., Godemann, R., Andersen, O. A., Fryatt, T., Courtney, S., Hallett, D., & Whittaker, M. A. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9284-1 · Cited by 57
Two ‘Golden Ratio’ indices in fragment-based drug discovery
Orita, M., Ohno, K., & Niimi, T. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.006 · Cited by 55
Søndergaard, C. R., Garrett, A. E., Carstensen, T., Pollastri, G., & Nielsen, J. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8016464 · Cited by 53
Fragment-Based Approach to Drug??Lead Discovery
Fattori, D., Squarcia, A., & Bartoli, S. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00002 · Cited by 52
Fragment-Based Discovery of BACE1 Inhibitors Using Functional Assays
Godemann, R., Madden, J., Krämer, J., Smith, M., Fritz, U., Hesterkamp, T., Barker, J., Hoeppner, S., Hallett, D. J., Cesura, A. M., et al. (2009) · Biochemistry · doi:10.1021/bi901061a · Cited by 51
Guertin, K. R., Setti, L., Qi, L., Dunsdon, R. M., Dymock, B. W., Jones, P. S., Overton, H. A., Taylor, M., Williams, G., Sergi, J. A., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00623-1 · Cited by 50
Combining Biophysical Screening and X-Ray Crystallography for Fragment-Based Drug Discovery
Hennig, M., Ruf, A., & Huber, W. (2011) · Topics in current chemistry · doi:10.1007/128_2011_225 · Cited by 48
Fragment‐based Identification of Hsp90 Inhibitors
Barker, J. J., Barker, O., Boggio, R., Chauhan, V., Cheng, R. K. Y., Corden, V., Courtney, S. M., Edwards, N., Falque, V. M., Fusar, F., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900011 · Cited by 48
Contributions of Computational Chemistry and Biophysical Techniques to Fragment-Based Drug Discovery
Gozalbes, R., Carbajo, R. J., & Pineda‐Lucena, A. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111224 · Cited by 38
Rastelli, G. (2009) · ChemMedChem · doi:10.1002/cmdc.200900251 · Cited by 37
Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)
Tjernberg, A., Hallén, D., Schultz, J., James, S. R., Benkestock, K., Byström, S. E., & Weigelt, J. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.014 · Cited by 34
Direct optical detection in fragment-based screening
Pröll, F., Fechner, P., & Proll, G. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2477-y · Cited by 32
Wada, C. K. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043388015 · Cited by 29
Fragment Screening and HIV Therapeutics
Bauman, J. D., Patel, D., & Arnold, E. (2011) · Topics in current chemistry · doi:10.1007/128_2011_232 · Cited by 24
Kinetic analysis and fragment screening with Fujifilm AP-3000
Rich, R. L., & Myszka, D. G. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.03.043 · Cited by 15
Picking up the pieces with FBDD or FADD: invest early for future success
Whittaker, M. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.011 · Cited by 15
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Cited by
The medicinal chemist's toolbox for late stage functionalization of drug-like molecules
Cernak, T., Dykstra, K. D., Tyagarajan, S., Vachal, P., & Krska, S. W. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00628g · Cited by 1,743
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
Key Topics in Molecular Docking for Drug Design
Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva-Jr, F. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184574 · Cited by 641
Plant-derived natural products for drug discovery: current approaches and prospects
Nasim, N., Sandeep, I. S., & Mohanty, S. (2022) · The Nucleus · doi:10.1007/s13237-022-00405-3 · Cited by 598
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Metadata
- Authors
- Erlanson, D. A.
- Venue
- Topics in Current Chemistry
- Publisher
- Springer Berlin Heidelberg
- Published
- 2011
- Volume
- 317
- Pages
- 1-32
- ISSN
- 0340-1022 (ISSN-L)
- 1436-5049
- OpenAlex
- W2173920250
- Cited by
- 259
- References
- 111
- FWCI
- 40.92
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.